Navigation Links
Dendreon Statement on CMS National Coverage Analysis
Date:6/30/2010

SEATTLE, June 30 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced that the Centers for Medicare and Medicaid Services (CMS) today initiated a National Coverage Analysis (NCA) of PROVENGE® (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC). PROVENGE is the first in a new therapeutic class known as autologous cellular immunotherapies.

In CMS's announcement of the NCA, CMS is requesting public comments on the effects of PROVENGE on health outcomes in patients with prostate cancer.  It is not a change in Medicare coverage policy. 

NCAs do not impact existing coverage decisions, nor do they restrict local Medicare contractors from covering PROVENGE.  Therefore, Medicare beneficiaries are still able to access PROVENGE and private payers can also still cover PROVENGE.

Dendreon welcomes the opportunity to continue our discussions with CMS about how PROVENGE will be provided to Medicare beneficiaries, particularly given the survival benefit and safety profile of PROVENGE.  We plan on continuing to work closely with CMS during this process to ensure patients with advanced prostate cancer have broad access to PROVENGE.

Clinical Trial Results Supporting U.S. Food and Drug Administration (FDA) Approval

Three Phase 3 studies involving 737 patients were submitted to FDA to support licensure. The pivotal study was the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) trial (D9902B), a 512-patient, multi-center, randomized, d
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting
2. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
3. Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
4. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
5. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
6. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
7. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
8. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
11. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Oct. 16 AngioGenex Inc. (OTC,Bulletin Board: AGGX.OB) ... molecules that are potent inhibitors of the Id ... filing of this patent,constitute major milestones in the ... Dr. Richard Salvador, President and CEO, and the,former ...
... Oct. 16 When eighty-six-year-old,Keith Hora went to see ... University of Newcastle in Australia, he was told he ... been diagnosed with stage III melanoma, one,of the most ... had multiple melanoma reoccurrences in the previously treated,area of ...
Cached Medicine Technology:AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer 2Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years 2
(Date:7/9/2014)... ways that cells are regulated, scientists at Rockefeller University ... more likely to metastasize. , What,s more, the protein ... two other proteins that are normally linked to neurodegeneration, ... have unexpected ties. , The study, which appears ... points to the possibility of new cancer therapies that ...
(Date:7/9/2014)... of stromal support cells and immune cells and ... in the development of diseases could open new ... was the conclusion of a review article by scientists ... Nature . , Prof. Peter Carmeliet: "Consider the ... of cancer cells has been examined in minute detail ...
(Date:7/9/2014)... have found that fecal transplantation is effective and safe ... This is the result of a study led by ... Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. The ... advance of print in the American Journal of ... C. diff , has increased to epidemic proportions over ...
(Date:7/9/2014)... Researchers from The Miriam Hospital have found that ... are also depressed have difficulty sticking to a ... true for women, and screening and brief treatment ... treatment. The study and its findings are published ... , Chronic obstructive pulmonary disease is a common ...
(Date:7/9/2014)... French . ... teens, including brain structure and function, personality, life experiences and ... on to develop binge drinking within the next two years. ... such as life events and a family history of drug ... or not the child had had a single drink at ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Wake-up call for more research into cell metabolism 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:What drives a child to abuse alcohol? 2
... Reports of a study reports that married women is having ... men or unmarried women and the report finds out that ... compared to married women. // , ,Catherine Mercer, ... said. "That is, within a relationship, people who were less ...
... health as it induces lot of alterations in the metabolism ... of colorectal tumours, while drinking in moderation lowers the risk, ... was conducted by Joseph C. Anderson, M.D. and colleagues at ... patients were subject to a survey of drinking habits and ...
... high but critics are more concerned with the availability of ... available to the developing and under developed countries//. ... anytime, due to current global conditions, as there are serious ... continue people have started stock piling and storing stocks of ...
... above may have a sedentary lifestyle if they perceive that their ... earlier studies that fewer than 40 percent of adults aged 65 ... years of independent life., ,A new UCLA study found that ... one can do at an advanced age — were the most ...
... University have said they are trying to develop an ... against lung cancer//. , ,Experiments with mice have ... still needed before the new therapy could be used ... ,"In fact it's a paradox," said research scientist Christian ...
... 27: Union Health Minister Anbumani Ramadoss today fired another salvo at ... country. He said: "influence of mafias over such a regulatory body ... MCI is an autonomous body and the government has no say ... in its functioning. , ,He said a cleansing process ...
Cached Medicine News:Health News:Alcohol Consumption A Threat To Colorectal Tumours 2Health News:Flu Vaccine Can Be Used To Treat Lung Cancer 2
Inorganic phosphorus (UV method) reagent is for the quantitative determination of inorganic phosphorus in human serum....
For the quantitative determination of Inorganic Phosphorus in serum. Linearity: 12.0 mg/dl....
For the kinetic quantitative determination of g-Glutamyl Transferase in serum for manual and/or automated procedures....
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Medicine Products: